Antiemetics

Quick revision

Antiemetics are organised by the receptor driving the nausea, not by the drug class name: 5-HT3 antagonists for chemotherapy/postoperative nausea, dopamine D2 antagonists for the chemoreceptor trigger zone, H1/muscarinic antagonists for motion sickness, and NK1 antagonists for delayed chemotherapy-induced nausea — and each group carries a defining, receptor-linked harm rather than a generic side-effect list.

• Ondansetron and the other 5-HT3 antagonists block serotonin receptors both peripherally on vagal afferents in the gut and centrally in the chemoreceptor trigger zone, and prolong the QT interval in a dose-dependent way, with postmarketing Torsades de Pointes reported. (1)
• Metoclopramide is a dopamine D2 antagonist with prokinetic gut effects, but it carries a boxed warning for tardive dyskinesia, a movement disorder that is often irreversible, whose risk rises with treatment duration and cumulative dose — treatment beyond 12 weeks is specifically discouraged for that reason. (2)
• Prochlorperazine, a phenothiazine dopamine antagonist related to the antipsychotics, treats nausea through the same D2-blocking chemoreceptor-trigger-zone mechanism and shares the class's risk of extrapyramidal reactions and tardive dyskinesia with prolonged use. (3)
• Promethazine and meclizine are H1-antihistamines with anticholinergic activity that act on the vestibular apparatus and vomiting centre, making them the drugs of choice for motion sickness rather than for chemotherapy-induced nausea. (4)
• Promethazine injection carries a boxed warning for severe tissue injury, including gangrene, if it leaks outside the vein (extravasation) or is injected intra-arterially or subcutaneously; it must be given by deep intramuscular injection or through a running IV line. (4)
• Aprepitant and its prodrug fosaprepitant are neurokinin-1 (NK1) receptor antagonists used specifically to prevent delayed chemotherapy-induced nausea and vomiting, and they are clinically significant CYP3A4 substrates, inhibitors and inducers with real drug-interaction potential. (5)
• The organising exam logic is "which nausea, which receptor": vestibular/motion nausea responds to H1/muscarinic blockade, chemotherapy/postoperative nausea to 5-HT3 or dopamine blockade, and delayed chemotherapy nausea specifically to NK1 blockade — picking the wrong receptor family for the wrong trigger is the commonest conceptual error. (10)

Overview

Nausea and vomiting are not produced by a single pathway, which is why antiemetics cannot be organised the way, say, antibiotics are. At least four separate receptor systems converge on the brainstem's vomiting centre and chemoreceptor trigger zone: serotonin (5-HT3) receptors, activated heavily by chemotherapy and surgery through vagal afferents in the gut wall and directly in the trigger zone; dopamine (D2) receptors, densely expressed in the chemoreceptor trigger zone itself; histamine (H1) and muscarinic acetylcholine receptors, central to the vestibular pathway that produces motion sickness; and neurokinin-1 (NK1) receptors, bound by substance P and specifically implicated in the delayed phase of chemotherapy-induced nausea that starts more than a day after treatment. A rational choice of antiemetic starts with identifying which of these systems is actually driving the nausea in front of the clinician. (10)

Ondansetron is the prototype 5-HT3 antagonist and the drug most associated with preventing chemotherapy-induced and postoperative nausea and vomiting. Its defining risk is cardiac rather than gastrointestinal: the drug prolongs the QT interval in a dose-dependent manner, and postmarketing reports include Torsades de Pointes. This led the FDA to remove the single 32 mg intravenous dose from the label and to specifically recommend ECG monitoring in patients with electrolyte abnormalities such as hypokalaemia or hypomagnesaemia, congestive heart failure, bradyarrhythmias, or those taking other QT-prolonging drugs, and to avoid the drug altogether in congenital long QT syndrome. (1)

Metoclopramide and prochlorperazine both work by blocking dopamine D2 receptors in the chemoreceptor trigger zone, but that same receptor blockade produces extrapyramidal symptoms because D2 receptors are also central to normal motor control in the basal ganglia. Metoclopramide's label carries a boxed warning specifically for tardive dyskinesia, a repetitive, involuntary movement disorder that is often irreversible once established; the risk increases with both the duration of treatment and the total cumulative dose, which is why the label recommends against using metoclopramide for longer than 12 weeks except in rare cases where the benefit is judged to outweigh the risk. Prochlorperazine, a phenothiazine structurally related to the antipsychotics, carries a comparable extrapyramidal and tardive dyskinesia risk through the same dopamine-blocking mechanism, alongside its own sedative and anticholinergic effects. (2) (3)

Promethazine and meclizine belong to a mechanistically different group: H1-antihistamines with meaningful anticholinergic activity, acting on the vestibular apparatus and the vomiting centre rather than primarily on the chemoreceptor trigger zone. This is why they are the standard choice for motion sickness rather than for chemotherapy-induced nausea, and why sedation and dry mouth, not extrapyramidal symptoms, dominate their side-effect profile. Promethazine carries its own distinct and unrelated hazard: given intravenously it can cause severe tissue injury, including gangrene, if it leaks outside the vein or is inadvertently given intra-arterially or subcutaneously, which is why its label requires deep intramuscular injection or administration through a running, clearly patent intravenous line, and carries a boxed warning to that effect. (4)

Aprepitant, and its injectable prodrug fosaprepitant, target yet another receptor: neurokinin-1, bound by substance P, specifically implicated in the delayed phase of chemotherapy-induced nausea and vomiting that 5-HT3 antagonists alone control less well. Rather than a receptor-linked toxicity, this drug's defining pharmacological feature is drug-drug interaction potential: aprepitant is a substrate, moderate inhibitor and inducer of CYP3A4, so it is combined with chemotherapy and other drugs metabolised through that enzyme only with attention to the resulting interactions, and its labelling specifically flags reduced efficacy when co-administered with strong CYP3A4 inducers such as rifampin. (5)

Classification and drug examples

Antiemetics are grouped by the receptor they block, because that receptor also predicts both which type of nausea the drug treats well and which specific harm it carries.

Mechanism of action

Each antiemetic subclass blocks a different receptor along the pathway that produces nausea and vomiting: 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone, dopamine D2 receptors in the chemoreceptor trigger zone, histamine H1 and muscarinic receptors along the vestibular pathway to the vomiting centre, and neurokinin-1 receptors bound by substance P, which are particularly implicated in the delayed phase of chemotherapy-induced emesis. Which receptor is actually driving a given episode of nausea determines which class will work.

Molecular target

5-HT3 receptors (serotonin antagonists); dopamine D2 receptors (dopamine antagonists); histamine H1 and muscarinic acetylcholine receptors (antihistamine/anticholinergic antiemetics); neurokinin-1 receptors (NK1 antagonists)

Pharmacodynamic effect

Not applicable — these are receptor antagonists acting on the patient's own neural pathways, not on a pathogen

Effect kinetics

Onset within roughly 30 minutes to 2 hours for oral/IV dosing across the class; duration tracks each drug's own half-life rather than a shared kinetic profile

1. Chemotherapy, surgery or gut irritation releases serotonin from enterochromaffin cells

   Serotonin released from the gut wall activates 5-HT3 receptors on vagal afferent nerves, which relay the signal to the brainstem, and also acts directly on 5-HT3 receptors in the chemoreceptor trigger zone. (10)

2. 5-HT3 antagonists block that serotonin signal at both sites

   Ondansetron and related drugs competitively block 5-HT3 receptors peripherally on vagal afferents and centrally in the chemoreceptor trigger zone, interrupting the nausea signal at its source and at its relay point. (1)

3. Circulating toxins and drugs activate dopamine D2 receptors in the chemoreceptor trigger zone

   The chemoreceptor trigger zone sits outside the blood-brain barrier and is rich in dopamine D2 receptors, which is why circulating drugs and toxins can trigger nausea through this route. (10)

4. Dopamine antagonists block that D2 signal, but the same receptor family runs motor control

   Metoclopramide and prochlorperazine block D2 receptors in the chemoreceptor trigger zone to suppress nausea, but D2 receptors are also central to the nigrostriatal motor pathway, which is the anatomical basis for the extrapyramidal symptoms and tardive dyskinesia risk shared by this subclass. (2)

5. Vestibular stimulation activates histamine H1 and muscarinic receptors

   Motion sickness arises from a mismatch of vestibular and visual input that signals through H1 and muscarinic pathways to the vomiting centre, which is why antihistamines with anticholinergic activity, not 5-HT3 or D2 antagonists, are the standard treatment for this specific trigger. (4)

6. Substance P activates NK1 receptors, especially in delayed chemotherapy-induced nausea

   Substance P release and NK1 receptor activation are particularly implicated in the delayed phase of chemotherapy-induced nausea and vomiting, occurring more than 24 hours after chemotherapy, a phase that 5-HT3 antagonism alone controls less effectively. (5)

7. NK1 antagonists block that substance P signal

   Aprepitant and fosaprepitant (its prodrug, converted to aprepitant within about 30 minutes of infusion) block NK1 receptors, extending antiemetic coverage into the delayed phase when added to a 5-HT3 antagonist and a corticosteroid. (5)

Major clinical uses

Pharmacokinetics

• This page gives no dose regimens by design. Dose selection depends on the indication, the emetogenic trigger, renal/hepatic function and concomitant drugs, and belongs in a current prescribing reference used by the treating clinician.
• Only the NK1 antagonist subclass has meaningful CYP3A4 drug-interaction potential as its defining pharmacokinetic feature; the other three subclasses are differentiated mainly by receptor target and CNS penetration rather than by enzyme interactions. (5)

Adverse effects

Common

• Headache and constipation: Common with 5-HT3 antagonists such as ondansetron, reported in a meaningful minority of patients. (1)
• Sedation and dry mouth: Expected with the H1-antihistamine/anticholinergic subclass (promethazine, dimenhydrinate, meclizine) because of their central antihistaminergic and anticholinergic activity. (4)
• Restlessness and mild extrapyramidal symptoms: Reported with metoclopramide and prochlorperazine even at short-term, therapeutic dosing, distinct from the longer-term tardive dyskinesia risk. (2)

Serious adverse effects

• QT prolongation and Torsades de Pointes: Ondansetron prolongs the QT interval in a dose-dependent manner; postmarketing cases of Torsades de Pointes have been reported, which is why the single 32 mg IV dose was removed from the label. ECG monitoring is recommended in patients with electrolyte abnormalities, heart failure, bradyarrhythmia or concomitant QT-prolonging drugs; the drug is avoided in congenital long QT syndrome. (1)
• Tardive dyskinesia: Metoclopramide carries a boxed warning for tardive dyskinesia, a movement disorder that is often irreversible; risk rises with treatment duration and cumulative dose. Prochlorperazine carries a related risk through the same D2-blocking mechanism. Treatment beyond 12 weeks is specifically discouraged for metoclopramide; therapy is discontinued immediately if signs of tardive dyskinesia appear. (2) (3)
• Severe tissue injury, including gangrene, with promethazine extravasation: Promethazine given intravenously can cause severe chemical irritation and tissue damage, including gangrene, if it leaks outside the vein or is inadvertently given intra-arterially or subcutaneously. The label requires deep intramuscular injection or administration only through a clearly patent, freely running intravenous line, and carries a boxed warning to that effect. (4)
• Reduced antiemetic efficacy from CYP3A4 drug interaction: Concomitant strong CYP3A4 inducers such as rifampin can meaningfully reduce aprepitant/fosaprepitant plasma concentrations and antiemetic efficacy. Concomitant medications are reviewed for CYP3A4 interaction before starting an NK1 antagonist regimen. (5)

Drug-specific effects

• Ondansetron: The only drug in this class whose label change (removal of the 32 mg IV dose) was driven directly by a cardiac safety signal rather than an efficacy finding. (1)
• Metoclopramide: The only member with an explicit maximum-duration recommendation (12 weeks) written directly into its boxed warning. (2)
• Promethazine: The only member whose boxed warning concerns the injection technique itself rather than a systemic drug effect. (4)
• Fosaprepitant/aprepitant: The only member whose defining pharmacological property is CYP3A4 substrate/inhibitor/inducer behaviour rather than a receptor-linked organ toxicity. (5)

Contraindications, precautions and interactions

Contraindications

• Ondansetron: concomitant apomorphine (risk of profound hypotension and loss of consciousness); congenital long QT syndrome. (1)
• Metoclopramide: history of tardive dyskinesia; conditions where increased gastrointestinal motility is dangerous, such as GI haemorrhage, obstruction or perforation. (2)
• Promethazine: use in children under 2 years of age; subcutaneous or intra-arterial injection. (4)

Precautions

• 5-HT3 antagonists are used cautiously with other QT-prolonging drugs and in patients with electrolyte disturbance, heart failure or bradyarrhythmia. (1)
• Dopamine antagonists are used at the lowest effective dose for the shortest necessary duration given the tardive dyskinesia risk shared by the subclass. (2) (3)
• Promethazine and other sedating antihistamine antiemetics are used cautiously in patients with respiratory compromise, in the elderly, and alongside other CNS depressants. (4)
• Concomitant medications are reviewed for CYP3A4 interaction before and during aprepitant/fosaprepitant therapy, particularly chemotherapy agents metabolised through that enzyme. (5)

Drug interactions

• Other QT-prolonging drugs: Additive QT prolongation risk with ondansetron and related 5-HT3 antagonists. (1)
• Other CNS depressants: Additive sedation with promethazine, dimenhydrinate and meclizine. (4)
• Strong CYP3A4 inhibitors or inducers: Alter aprepitant/fosaprepitant exposure and efficacy, and aprepitant itself can raise plasma levels of other CYP3A4-metabolised drugs, including some chemotherapy agents. (5)
• Other dopamine antagonists or antipsychotics: Additive extrapyramidal symptom risk with metoclopramide or prochlorperazine. (2)

Comparison tables

High-yield exam pearls

• "Which nausea, which receptor" is the organising logic of this whole class. (10) Motion sickness, chemotherapy nausea and delayed chemotherapy nausea are driven by different receptor systems, so the same antiemetic will not work equally well for all three.
• Ondansetron's defining risk is cardiac, not gastrointestinal. (1) Dose-dependent QT prolongation, not a GI adverse effect, is why the 32 mg single IV dose was removed from the label.
• Metoclopramide's boxed warning specifies a 12-week treatment ceiling. (2) This is one of the few boxed warnings that names an explicit duration limit rather than just a risk category, directly reflecting that tardive dyskinesia risk tracks cumulative exposure.
• Promethazine's boxed warning is about how it is injected, not what it does systemically. (4) Severe tissue injury/gangrene from extravasation or wrong-route injection is a technique-linked hazard, distinct from the drug's antihistaminergic pharmacology.
• Aprepitant/fosaprepitant's defining property is CYP3A4 interaction, not organ toxicity. (5) It is the only antiemetic subclass here whose main prescribing hazard is a pharmacokinetic interaction rather than a direct receptor-linked adverse effect.

Common exam traps

• Trap: Reaching for a 5-HT3 antagonist for motion sickness. Actually: Motion sickness is driven by the vestibular H1/muscarinic pathway, not serotonin release from the gut, so an antihistamine like promethazine or meclizine is the better-matched choice. (4)
• Trap: Assuming metoclopramide's extrapyramidal risk only matters with long-term use. Actually: Restlessness and mild extrapyramidal symptoms are reported even at short-term therapeutic dosing, distinct from the longer-term, often-irreversible tardive dyskinesia the boxed warning addresses. (2)
• Trap: Treating ondansetron as risk-free because it is not sedating and not a dopamine antagonist. Actually: Its own defining risk, dose-dependent QT prolongation with reported Torsades de Pointes, is a real and label-driving cardiac hazard, not a benign trade-off for avoiding sedation or extrapyramidal effects. (1)
• Trap: Assuming aprepitant/fosaprepitant's only concern is nausea control. Actually: Its CYP3A4 substrate/inhibitor/inducer behaviour can meaningfully alter concomitant chemotherapy drug levels, which is arguably the more clinically important prescribing issue than its own antiemetic efficacy. (5)

Self-test questions

Answers are hidden until you open them. These questions are written from this page's cited content and are for study only — they are not clinical guidance.

1. A patient develops nausea from motion during a long car journey. Which antiemetic class is best matched to the mechanism?

   • 5-HT3 antagonists
   • NK1 antagonists
   • H1-antihistamines/anticholinergics
   • Dopamine D2 antagonists
   Show answer

   Answer: H1-antihistamines/anticholinergics

   Motion sickness arises through the vestibular pathway signalling via histamine H1 and muscarinic receptors, which is why antihistamines with anticholinergic activity such as promethazine or meclizine, not 5-HT3, NK1 or dopamine antagonists, are the standard choice. (4)

2. Why was the 32 mg single intravenous dose of ondansetron removed from its label?

   • It was found to be ineffective
   • It was linked to significant dose-dependent QT-interval prolongation
   • It caused unacceptable sedation
   • It interacted with all chemotherapy agents
   Show answer

   Answer: It was linked to significant dose-dependent QT-interval prolongation

   Ondansetron prolongs the QT interval in a dose-dependent manner, and the 32 mg single IV dose was specifically associated with a clinically significant QT effect, leading to its removal from the label. (1)

3. What does metoclopramide's boxed warning specifically caution against?

   • Severe hepatotoxicity with any use
   • Tardive dyskinesia, with a recommendation against use beyond 12 weeks
   • Anaphylaxis on first exposure
   • Irreversible renal failure
   Show answer

   Answer: Tardive dyskinesia, with a recommendation against use beyond 12 weeks

   Metoclopramide's boxed warning addresses tardive dyskinesia, a movement disorder that is often irreversible, whose risk rises with treatment duration and cumulative dose, leading to the 12-week treatment recommendation. (2)

4. Why must promethazine injection be given by deep intramuscular injection or through a clearly running IV line rather than any convenient route?

   • To improve its taste
   • To avoid severe tissue injury, including gangrene, from extravasation or intra-arterial/subcutaneous injection
   • To prevent nausea from the injection itself
   • To speed up hepatic metabolism
   Show answer

   Answer: To avoid severe tissue injury, including gangrene, from extravasation or intra-arterial/subcutaneous injection

   Promethazine carries a boxed warning for severe chemical tissue injury, including gangrene, if it leaks outside the vein or is given by the wrong route, which is why administration technique is specifically restricted. (4)

5. What is the main pharmacological reason aprepitant/fosaprepitant requires careful review of concomitant medications?

   • It is highly protein-bound with no metabolism
   • It is a substrate, inhibitor and inducer of CYP3A4, with real potential to alter levels of co-administered drugs including some chemotherapy agents
   • It has no known drug interactions
   • It is exclusively eliminated unchanged by the kidney
   Show answer

   Answer: It is a substrate, inhibitor and inducer of CYP3A4, with real potential to alter levels of co-administered drugs including some chemotherapy agents

   Aprepitant acts as a CYP3A4 substrate, moderate inhibitor and inducer, giving it meaningful potential to alter plasma levels of other CYP3A4-metabolised drugs, which is the class's defining pharmacokinetic feature. (5)

6. A patient needs an antiemetic for the delayed phase of chemotherapy-induced nausea that a 5-HT3 antagonist alone has not controlled. Which receptor-targeted class is added specifically for this?

   • H1-antihistamines
   • NK1 antagonists
   • Anticholinergics
   • Saline osmotic agents
   Show answer

   Answer: NK1 antagonists

   The delayed phase of chemotherapy-induced nausea is particularly linked to substance P and NK1 receptor activation, which is why NK1 antagonists such as aprepitant/fosaprepitant are added to a 5-HT3 antagonist and corticosteroid regimen for this specific phase. (5)

Frequently asked questions

References

1. ONDANSETRON tablet / injection — prescribing information DailyMed, U.S. National Library of Medicine
2. REGLAN (metoclopramide hydrochloride) tablet — prescribing information DailyMed, U.S. National Library of Medicine
3. PROCHLORPERAZINE MALEATE tablet, film coated — prescribing information DailyMed, U.S. National Library of Medicine
4. PHENERGAN (promethazine HCl) tablet / injection — prescribing information DailyMed, U.S. National Library of Medicine
5. EMEND (fosaprepitant dimeglumine) for injection — prescribing information DailyMed, U.S. National Library of Medicine
6. GRANISETRON HYDROCHLORIDE tablet, film coated — prescribing information DailyMed, U.S. National Library of Medicine
7. AKYNZEO (netupitant and palonosetron) capsule — prescribing information DailyMed, U.S. National Library of Medicine
8. MOTION SICKNESS RELIEF (meclizine HCl) tablet — OTC drug facts label DailyMed, U.S. National Library of Medicine
9. DRAMAMINE ORIGINAL FORMULA (dimenhydrinate) tablet — OTC drug facts label DailyMed, U.S. National Library of Medicine
10. Ondansetron StatPearls Publishing / NCBI Bookshelf

Related drug classes

• Proton pump inhibitors
• H2-receptor antagonists
• Antacids and alginates
• Antispasmodics
• Laxatives and antidiarrhoeals

Back to the Gastrointestinal drugs classification · Pharmacology Study Corner